Tyrosine kinase inhibitors (TKI), including imatinib (IM), improve the outcome of CML therapy. However, TKI treatment is long-term and can induce resistance to TKI, which often leads to a poor clinical outcome in CML patients. Here, we examined the effect of continuous IM exposure on intracellular energy metabolism in K562 cells, a human Philadelphia chromosome-positive CML cell line, and its subsequent sensitivity to anti-cancer agents. Contrary to our expectations, we found that continuous IM exposure increased sensitivity to TKI. Cancer energy metabolism, characterized by abnormal glycolysis, is linked to cancer cell survival. Interestingly, glycolytic activity was suppressed by continuous exposure to IM, and autophagy increased to maintain cell viability by compensating for glycolytic suppression. Notably, increased sensitivity to 
Philadelphia chromosome, which results from reciprocal translocation of t (9;22) . 1 The resulting BCR/ABL fusion protein activates survival pathways, including PI3K/Akt, JAK/STAT, and Ras/Raf. 2, 3 These pathways also trigger abnormal proliferation of CML cells and increase their resistance to apoptosis. IM, a specific BCR/ABL TKI, yields a marked improvement in CML patient survival; 4 however, suboptimal responses or IM-resistance often makes it difficult to continue therapy long term. [5] [6] [7] Point mutations within the ABL kinase domain (eg, Y235F/H, E255K/V, T315I, and H396P/R) are associated with IM-resistance. 8, 9 To counter this, second and third generation TKI (eg, dasatinib, nilotinib, bosutinib, and ponatinib) were developed. 10 Alternatively, multiple studies suggest that overexpression of BCR/ABL-dependent or -independent signaling pathways correlates with resistance to or efficacy of TKI, regardless of the point mutations mentioned above.
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For example, BCR/ABL-dependent activation of the PI3K/Akt pathway contributes to the survival of CML cells during the early phase of IM-resistance, 12 and the JAK2/STAT5 pathway induces anti-apoptotic effects that thwart the actions of IM. 13 Also, deficiency of p53
in BCR/ABL-transformed cells decreases their sensitivity to IM in a BCR/ABL-independent way. 14 Thus, targeting intracellular signaling may be an effective CML therapy.
BCR/ABL tyrosine kinase promotes not only cell proliferation and survival but also glycolysis. 15 IM suppresses glycolysis in human CML cells by inhibiting several glycolytic enzymes and decreasing glucose uptake. 16, 17 Moreover, IM-resistant cells express high levels of HIF-1a, which activates glucose transporters and many glycolytic enzymes. 18 Thus, the efficacy of IM is closely associated with energy metabolism, particularly glycolysis. In addition, cancer cells obtain most of their energy and ATP from glycolysis, even under aerobic conditions. 19 Targeting hallmarks of energy metabolism has a place in cancer therapy. For instance, suppressing glycolysis in human tumors using 2-deoxy-D-glucose, a hexokinase inhibitor, increases the efficacy of doxorubicin and paclitaxel. 20 Therefore, molecules or machineries that interfere with cancer energy metabolism, including aerobic glycolysis, may improve the efficacy of TKI and improve CML therapy.
Here, we first examined changes in the IM-sensitivity of K562 cells, a human CML cell line, continuously exposed to IM. We expected that the K562 cells would become resistant to IM; however, these cells actually became more sensitive to IM and other TKI. In addition, continuous exposure to IM inhibited glycolysis, which induced autophagy as a compensatory mechanism to maintain cell viability. Importantly, continuous exposure to IM increased the sensitivity to TKI by suppressing S6K1 and activating AMPK, both of which play an important role in regulating glycolysis and autophagy.
Furthermore, a mTORC1/S6K1 signaling suppressor and an AMPK activator (rapamycin and metformin, respectively) increased sensitivity to TKI, and mediated synergistic anti-cancer effects by inhibiting autophagy in the presence of TKI. Thus, we propose that altering intracellular signaling pathways that affect cancer metabolism (using S6K1 suppressors and AMPK activators) and blocking autophagy will improve TKI treatment for CML. 
| Flow cytometric detection of dead cells
Collected cells were stained with the Zombie NIR TM Fixable Viability kit (BioLegend, San Diego, CA, USA) to distinguish dead cells from live cells. Data acquisition was carried out using an EC800 Flow Cytometry Analyzer (Sony, Tokyo, Japan).
| Measurement of cellular lactate release
Release of cellular lactate was measured as described previously. 22 
| BrdU incorporation assay
To assess cell proliferation, K562 cells continuously exposed to IM were incubated with 10 lmol/L BrdU (Tokyo Chemical Industry Co., Tokyo, Japan) for 1 hour. BrdU-positive cells were identified using an EC800 Flow Cytometry Analyzer (Sony).
| Western blot analysis
Cells were lysed on ice in lysis buffer containing PBS (pH 7.4), 1% Triton X-100, and protease and phosphatase inhibitor cocktails (Roche, Mannheim, Germany). Identical amounts of protein from each sample were separated in SDS-PAGE gels and then transferred to PVDF membranes (Merck Millipore, Berlin, Germany).
After membrane blocking, the blots were probed with primary antibodies specific for BCR, p-BCR (T177), HIF-1a, LC3B, p70S6K, p-p70S6K (T389), AMPKa, p-AMPKa (T172), and GAPDH (all purchased from Cell Signaling Technologies, Beverly, MA, USA).
Immunolabeled proteins were detected using a HRP-labeled anti- 
| Transmission electron microscopy
Cells were prepared for transmission electron microscopy and observed as previously described. [23] [24] [25] Images were obtained under a JEM-1400 electron microscope (JEOL, Tokyo, Japan) at 2500-10 0009 nominal magnification.
| Statistical analysis
All data were expressed as the mean AE SD of at least 3 independent experiments. Statistical analysis was carried out using Student's t test or analysis of variance followed by the Bonferroni test where applicable. A P value of <.05 was considered significant. Figure 1D ). K562 cells continuously exposed to 0.1 lmol/L IM for 3 weeks are named "K562-IM3w" cells.
Next, to examine whether increased IM-sensitivity of K562-IM3w cells is also true for other TKI, we exposed K562-IM3w cells to dasatinib, nilotinib, bosutinib, or ponatinib, or to the classical anticancer agents methotrexate, cytarabine, cisplatin, and vincristine. As observed for IM, other TKI were more effective against K562-IM3w cells than against the parental cells ( Figure 1E ). By contrast, the classical anti-cancer agents tended to be less effective against K562-IM3w cells ( Figure 1E ). These findings suggest that continuous exposure to IM sensitizes K562 cells to TKI.
| Continuous exposure to IM suppresses glycolysis and increases autophagy
Aerobic glycolysis is a hallmark of cancer energy metabolism, and targeting glycolytic pathways sensitizes several cancer cells to chemotherapeutic agents. 27 As IM suppresses glycolysis, 16, 17 we hypothesized that altered intracellular energy metabolism, particularly glycolysis, by continuous exposure to IM increases sensitivity to TKI. As in previous reports, we confirmed that lactate production, the final step of glycolysis, was reduced in K562 cells exposed to IM HIRAO ET AL.
| 123
( Figure 2A ). Interestingly, a significant decrease in lactate production was observed even at concentrations lower than those at which marked cell death occurred (LD 50 , 11.72 AE 0.462 lmol/L). Also, lactate production remained low when cells were exposed to 0.1 lmol/ L IM for 4 weeks ( Figure 2B ). Furthermore, we observed reduced expression of HIF-1a protein, which contributes to increased glycolysis and proliferation of cancer cells, 28, 29 and reduced expression of mRNA encoding glycolytic enzymes hexokinase 2 and lactate dehydrogenase A in K562-IM3w cells ( Figure 2C,D) . Inhibiting glycolysis using 2-deoxy-D-glucose increases the efficacy of several anti-cancer agents; 20 however, inhibiting glycolysis in K562 cells using 2-deoxy-D-glucose did not increase their sensitivity to IM ( Figure 2E ), despite marked inhibition of glycolysis ( Figure S1 ). These results suggested that increased sensitivity of K562 cells to TKI was not directly related to inhibition of glycolysis; therefore, other factors needed to be considered.
We previously proposed that autophagy is induced to maintain energy homeostasis and survival of ALL cells when glycolysis is suppressed. 22 Therefore, we assumed that autophagy would be increased by continuous exposure to IM, which may hint at the cause underlying increased sensitivity to TKI. We found that expression of LC3-II, a characteristic marker of autophagosome formation, was higher in K562-IM3w cells than in parental cells ( Figure 3A) .
Also, the distribution pattern of aggregated GFP-LC3 in K562-IM3w cells supported IM-induced autophagosome formation ( Figure 3B ).
Moreover, autophagic vacuoles in K562-IM3w cells were clearly visible by transmission electron microscopy ( Figure 3C ). In addition, to rule out the possibility that the appearance of autophagic vacuoles We also focused on another signaling molecule, AMPK, which is a sensor of intracellular energy status. 31 As AMPK is activated by energy metabolic stresses (eg, glucose deprivation) to maintain intracellular ATP levels, 32 Figure 7B ). 37 We next confirmed that the sensitivity of Ba/F3-BCR/ABL cells to IM was dose-dependent (Figure 7C) . Suppressing S6K1 and activating AMPK using rapamycin (10 nmol/L) and metformin (1 mmol/L), respectively, increased sensitivity to IM (0.7 lmol/L) ( Figure 7D ). These data suggest that altered intracellular signaling as a result of suppression of S6K1 and activation of AMPK increases the anti-cancer effect of inhibiting BCR/ABL.
| DISCUSSION
Here, we show that continuous exposure to IM increases the sensitivity of K562 cells to TKI. We also confirmed that IM-mediated effects. 41, 42 There is little information about the relationship between AMPK and TKI, but we assume that activating AMPK by continuous exposure to IM might increase sensitivity to TKI by affecting the above signaling pathways.
Here, we showed that continuous exposure to IM suppresses glycolysis and drives autophagy. Furthermore, we found that mitochondrial activity in K562 cells was increased by continuous exposure to IM ( Figure S6 ; Appendix S1). These findings are comparable with those described in our previous report showing that increased autophagy as a result of inhibited glycolysis promotes mitochondrial activity to overcome the energy shortage in ALL cells. 22 These findings are supported by other studies arguing that IM increases intracellular glutamate levels, a major intermediate in the mitochondrial Krebs cycle, 17 and that inactivation of BCR/ABL promotes mitochondrial fatty acid oxidation. 43 Hence, continuous exposure to IM (probably at concentrations too low to cause cytotoxicity) may dynamically alter intracellular energy metabolism to maintain intracellular ATP levels. Activated mitochondrial oxidative phosphorylation produces a large amount of ATP, but this process generates ROS as a natural byproduct, causing oxidative damage to mitochondrial lipids, cellular DNA, and functional proteins. 44 We showed that IM-induced autophagy reduces intracellular ROS levels ( Figure S7 ; Appendix S1), suggesting that autophagy might work cytoprotectively by lowering intracellular stress generated by mitochondria as compensation for energy acquisition. Therefore, co-treatment with autophagy inhibitors and TKI is expected to show synergistic anticancer effects. Recent studies suggest that epigenetic patterns are affected by nutrients and their metabolites, which likely change in different environments. 45 The high reliance of cancer cells on glycolytic pathways may be a consequence of reprogramming energy metabolism. 46 Although the mechanisms underlying epigenomic control of cancer energy metabolism have not been fully elucidated, some studies provide insight. For example, LSD1, which suppresses gene expression by removing the methyl group from histone H3, 47 plays a key role in the epigenetic plasticity of cell metabolism. Sakamoto et al 48 showed
that inhibiting LSD1 reduced glycolytic activity and activated mitochondrial respiration in hepatocellular carcinoma cells, and that this metabolic shift was related to expression of HIF-1a protein. Here, we showed that continuous exposure to IM reduced expression of the HIF-1a protein, thereby suppressing glycolysis; this is comparable with the findings in LSD1-inhibited cancer cells described above.
In addition, IM-treated cells reduced expression of mRNA encoding S6K1 and AMPK; this was also observed in patients subjected to IM treatment. This may be a result of genomic reprogramming, which affects energy metabolism in CML cells. Although knowledge about TKI-mediated epigenetic regulation is scarce, future studies should uncover the mechanism by which altered intracellular signaling pathways/molecules and energy metabolism affect sensitivity to anti-cancer agents.
A previous study shows that various molecular signaling inhibitors have anti-cancer effects. 49 Here, we showed that rapamycinand metformin-mediated disturbance of signaling related to intra- 
